26328-04-1

• 常用中文名：马来酸桂哌齐特
• 常用英文名：Cinepazide maleate
• CAS号：26328-04-1
• 分子式：C₂₆H₃₅N₃O₉
• 分子量：533.57100
• 相关类别： 原料药 循环系统用药 防治心绞痛药
• 发布时间：2018-09-27 08:42:48
• 更新时间：2026-07-01 18:17:53
• 1.脑血管疾病：脑动脉硬化、一过性脑缺血、脑血栓、脑栓塞、脑出血及脑外伤后遗症。
  2.心血管疾病，用于动脉硬化、心绞痛，心肌梗塞患者应配合相关药物治疗。
  3.眼底血管性疾病、缺血所致耳蜗前庭功能失调、突发性耳聋、耳鸣。
  4.糖尿病引起的微循环障碍（糖尿病足、糖尿病视网膜病变等）。
  5.其它外周血管性疾病:血栓闭塞性脉管炎、动脉炎、雷诺氏病、下肢动脉粥样硬化等。

名称

• 中文名: 马来酸桂哌齐特
• 英文名: Cinepazide maleate
• 中文别名: 马来酸桂哌齐特,10 MM DMSO 溶液; 抑制剂Cinazide Maleate; 来酸桂哌齐特; 马来酸桂哌齐特杂质; 马来酸西尼帕齐德; (E)-1-{4-[(3,4,5’-三甲氧基肉桂酰基)]-1-哌嗪}乙酰吡咯啶顺丁烯二盐酸; 马来酸桂哌奇特; 马来酸桂哌齐特(为自有专利合成路线); 桂哌齐特杂质; 1-(吡咯烷-1-基甲酰甲基)-4-(3,4,5-三甲氧基苯丙烯酰基)哌嗪马来酸盐; 1-[(1-吡咯烷甲酰)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪顺丁烯二酸盐
• 英文别名: Cinazide maleate //BP; brendil; GenBank AF247021; piperazine, 1-((1-pyrrolidinylcbonyl)methyl)-4-(3',4',5'-trimethoxycinnamoyl) 1-((1-pyrrolidinylcbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazi ne m 1-(4-((3',4',5'-trimethoxycinnamoyl)-1-piperazinyl)acetyl)pyrrolidine maleate 4-(3,4,5-trimethoxycinnamoyl)-1-(1-pyrrolidinyl)cbonylmethylpiperazine male brendil; Cinazide maleate, 10 mM in DMSO; Cinazide Impurities1; Cinazide maleate (MD-67350); md67350; EINECS 247-613-1; (E)-1-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]-3-(3,4,5-trimethoxyphenyl)-2-propen-1-one; 2-Propen-1-one (1-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]-3-(3,4,5-trimethoxyphenyl); 1-(2-oxo-2-pyrrolidin-1-ylethyl)-4-[3-(3,4,5-trimethoxyphenyl)acryloyl]piperazine monomaleate; 1-(1-Pyrrolidinylcbonyl)methyl)-4-(3',4',5'-trimethoxycinnamoyl); Cinazide Mateate; 4-(3,4,5-trimethoxycinnamoyl)-1-(1-pyrrolidinyl)cbonylmethylpiperazinemale; 2-Propen-1-one, 1-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]-3-(3,4,5-trimethoxyphenyl)-, (2Z)-2-butenedioate (1:1); 1-(4-((3’,4’,5’-trimethoxycinnamoyl)-1-piperazinyl)acetyl)pyrrolidinemaleate; Cinazide Impurities1385; maleatedecinepazide; Cinepazide Mateate; MFCD01320526; 1-[(1-Pyrrolidinylcbonyl)methyl]-4-(3,4,5-trimethoxycinnamoyl)piperazine maleate; DD-3357; maleatedecinazide; piperazine,1-((1-pyrrolidinylcbonyl)methyl)-4-(3’,4’,5’-trimethoxycinnamoyl); Reaxys ID; 1-((1-pyrrolidinylcbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazinem; (E)-1-(4-(2-oxo-2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one maleate; Cinepazide (Maleate); CINAZIDE MALEATE; 1-(4-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one maleate; vasodistal

物化性质

• 密度: 1.256
• 沸点: 637.8ºC at 760 mmHg
• 熔点: 173 °C(dec.)
• 分子式: C₂₆H₃₅N₃O₉
• 分子量: 533.57100
• 闪点: 339.5ºC
• 精确质量: 533.23700
• PSA: 146.15000
• LogP: 1.01770
• 外观性状: 白色或灰白色结晶粉末
• 蒸汽压: 3.65E-16mmHg at 25°C
• 储存条件: -20°C
• 计算化学:

  1、 氢键供体数量：0

  2、 氢键受体数量：10

  3、 可旋转化学键数量：7

  4、 拓扑分子极性表面积（TPSA）：152

  5、 重原子数量：38

  6、 表面电荷：-2

  7、 复杂度：694

  8、 同位素原子数量：0

  9、 确定原子立构中心数量：0

  10、 不确定原子立构中心数量：0

  11、 确定化学键立构中心数量：2

  12、 不确定化学键立构中心数量：0

  13、 共价键单元数量：2

• 更多:

  1. 性状：为白色结晶.无臭,味苦.; 2. 密度（g/mL,25/4℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：135

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,5.2kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：未确定

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25ºC）：未确定

  12. 饱和蒸气压（kPa,60ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：极易溶于冰醋酸.

生物活性

• 描述: Cinepazide马来酸盐是血管扩张剂。
• 相关类别:
  信号通路 >> 其他 >> 其他
  研究领域 >> 心血管疾病
• 参考文献:

  [1]. Akashi, A., et al., [Cardiovascular pharmacology of cinepazide, a new cerebral vasodilator (author's transl)]. Nihon Yakurigaku Zasshi, 1979. 75(5): p. 507-16.

  [2]. Muramatsu, I., et al., Effects of cinepazide on the purinergic responses in the dog cerebral artery. Pharmacology, 1984. 28(1): p. 27-33.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : TM2785100 CHEMICAL NAME : Piperazine, 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3',4',5'-trimet hoxycinnamoyl)-, maleate CAS REGISTRY NUMBER : 26328-04-1 LAST UPDATED : 199309 DATA ITEMS CITED : 13 MOLECULAR FORMULA : C22-H31-N3-O5.C4-H4-O4 MOLECULAR WEIGHT : 533.64 WISWESSER LINE NOTATION : T6N DNTJ AV1U1R CO1 DO1 EO1& D1V- AT5NTJ &QV1U1VQ -C HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1310 mg/kg TOXIC EFFECTS : Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic REFERENCE : THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 710 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,407,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 414 mg/kg TOXIC EFFECTS : Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic REFERENCE : THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1 gm/kg TOXIC EFFECTS : Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic REFERENCE : THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 946 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,407,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 617 mg/kg TOXIC EFFECTS : Behavioral - tremor Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic REFERENCE : THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 29,29,1974 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 62400 mg/kg/26W-I TOXIC EFFECTS : Lungs, Thorax, or Respiration - other changes Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 17,83,1979 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 672 mg/kg SEX/DURATION : female 15-21 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,559,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 16800 mg/kg SEX/DURATION : female 15-21 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - physical REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,559,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 240 mg/kg SEX/DURATION : female 6-15 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,546,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 10600 mg/kg SEX/DURATION : female 6-15 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,546,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 312 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,572,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 910 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,572,1979

安全

• 符号: GHS07
• 信号词: Warning
• 危害声明: H302
• 警示性声明: P301 + P312 + P330
• 危害码 (欧洲): Xi
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 3
• 海关编码: 2942000000

制备

1. 3,4,5-三甲氧基肉桂酰氯的制备

在反应瓶中加入3,4,5-三甲氧基肉桂酸2.3g(9.8mmol)和环己烷10ml,搅拌悬浮,搅拌下滴加氯化亚砜7.2g,滴加时控制温度不超过20ºC,加毕,搅10min.室温放置过夜.低于50ºC,减压蒸除氯化亚砜,加入环己烷2.4ml重蒸一次,溶于6ml二氯甲烷中备用.

2. 1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪的制备

在反应瓶中加入(1-四氢吡咯羰基)甲基哌嗪1.6g(8.1mmol)和二氯甲烷16ml,搅拌溶解,冰浴冷却及搅拌下滴加上步含3,4,5-三甲氧基肉桂酰氯的二氯甲烷溶液,滴加过程保持内温10 ºC,加毕,室温搅拌4h.加入水10ml,充分振摇.分出水层,有机层加入15%盐酸10ml,充分振摇.将两次水层合并,用5%NaOH溶液中和至pH9~10.二氯甲烷(10ml×3)提取,合并有机层,饱和NaCl水溶液(10ml×2)洗,无水Na2SO4干燥过夜.过滤,滤液减压蒸除回收溶剂#得到棕色黏稠剩余物1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪2.34g,收率69.4%.

3. 1-[(1-四氢吡咯羰基)甲基]-4(3,4,5-三甲氧基肉桂酰基)哌嗪马来酸盐(马来酸桂哌齐特)的合成

在反应瓶中加入1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪0.42g(1.006mol)和无水乙醇4.4ml,搅拌溶解.在另一反应瓶中加入马来酸0.14g(1.2mmol)和无水乙醇0.6ml,搅拌溶解,然后加1-[(1-四氢吡咯羰基)甲基]-4-(3,4,5-三甲氧基肉桂酰基)哌嗪的无水乙醇溶液,室温搅拌10min后,静置6h.得到1-[(1-四氢吡咯羰基)甲基]-4(3,4,5-三甲氧基肉桂酰基)哌嗪马来酸盐(马来酸桂哌齐特)0.27g色结晶,收率51.9%,mp130~132 ºC.

海关

海关编码	2942000000